SynthesisCell communication and signaling : CCS2023
Applications of lung cancer organoids in precision medicine: from bench to bedside.
Synthesis in Cell communication and signaling : CCS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Advancing lung organoids toward clinical applications: a global perspective on research focus and future directions.Frontiers in medicine · 2025Pooled it
- Neural regulation in lung cancer: from mechanisms to new therapeutic perspectives.Clinical and experimental medicine · 2026Review
- Patient-derived three-dimensional lung tumor models to evaluate response to therapy.NPJ precision oncology · 2026Article
- Organoid models: Regulations and prospects for the development of investigational new drugs.Chinese medical journal · 2026Review
- Bibliometric analysis of lung cancer organoid research: trends and emerging areas of study.Journal of thoracic disease · 2026Article
- A patient-derived organoid model identifies TP53-dependent gemcitabine sensitivity in spinal chordoma.Discover oncology · 2026Article
- Human airway organoids as a versatile model to study BSL-4 virus replication and pathogenesis.Scientific reports · 2026Article
- TargetingPharmaceuticals (Basel, Switzerland) · 2026Article
- Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.iScience · 2026Review
- UCK2 Drives Lung Adenocarcinoma Progression and Immune Dysregulation via the RHEB/mTOR Signaling Axis.Oncology research · 2026Article
- MicroRNA‑199a‑3p suppresses non‑small cell lung cancer progression by targeting FTO to enhance m6A‑mediated downregulation of MZF1 and its transcriptional activation of CLDND1.Molecular medicine reports · 2026Article
- Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids.Frontiers in oncology · 2026Article
- Constructing an ultrasound-assisted organoid model for tumor management.Discover oncology · 2025Review
- Mechanotransduction-Epigenetic Coupling in Pulmonary Regeneration: Multifunctional Bioscaffolds as Emerging Tools.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Persistent lineage plasticity driving lung cancer development and progression.Clinical and translational medicine · 2025Review
- The expression and prognosis for Aurora kinases in human non-small cell lung cancer.Discover oncology · 2025Article
- GIMAP8 could serve as a potential prognostic factor for lung adenocarcinoma and is closely related to immunity.Scientific reports · 2025Article
- Standardization and consensus in the development and application of bone organoids.Theranostics · 2025Review
- Application and development of Organ-on-a-Chip technology in cancer therapy.Frontiers in oncology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment, the 5-year survival rate for lung cancer patients is only 10-20%. There is an urgent need to develop more reliable preclinical models and valid therapeutic approaches. Patient-derived organoids with highly reduced tumour heterogeneity have emerged as a promising model for high-throughput drug screening to guide treatment of lung cancer patients. Organoid technology offers a novel platform for disease modelling, biobanking and drug development. The expected benefit of organoids is for cancer patients as the subsequent precision medicine technology. Over the past few years, numerous basic and clinical studies have been conducted on lung cancer organoids, highlighting the significant contributions of this technique. This review comprehensively examines the current state-of-the-art technologies and applications relevant to the formation of lung cancer organoids, as well as the potential of organoids in precision medicine and drug testing. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.